Welcome to our dedicated page for ReposiTrak SEC filings (Ticker: TRAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ReposiTrak, Inc. (NYSE: TRAK), a Nevada corporation that operates a cloud-based food traceability, compliance and supply chain data platform. Through these filings, investors can review how the company reports its financial results, corporate actions and governance matters in accordance with SEC requirements.
ReposiTrak’s recent Form 8-K filings include disclosures about quarterly cash dividend declarations on its common stock, authorization of a 10b5-1 share repurchase program under a broader repurchase authorization, earnings releases for fiscal quarters and years, and the results of its annual meeting of stockholders. These current reports also reference attached press releases and earnings call transcripts that provide additional detail on financial performance, capital allocation and operational commentary.
In addition to current reports, ReposiTrak files periodic reports such as Form 10-K annual reports and Form 10-Q quarterly reports, which contain audited or reviewed financial statements, management’s discussion and analysis, risk factor disclosures and information on its business, including its focus on food traceability, regulatory compliance and supply chain solutions delivered through cloud-based applications.
Stock Titan’s filings page is designed to surface these documents as they are made available on EDGAR and to pair them with AI-powered summaries that explain the key points in accessible language. Users can quickly identify items such as dividend announcements, share repurchase authorizations, earnings results and shareholder meeting outcomes, and then drill into the underlying SEC reports for more detail. This same interface can also be used to monitor insider and executive transactions reported on forms such as Form 4, as those become available for ReposiTrak insiders.
ReposiTrak, Inc. insider filing shows planned charitable-related stock sales by entities associated with CEO and 10% owner Randall K. Fields. A Rule 10b5-1 trading plan for RK Fields Charitable 2022, LLC executed sales of ReposiTrak common stock on three days: 1,000 shares on 01/14/2026 at a weighted average price of $11.094, 3,600 shares on 01/15/2026 at $11.0786, and 2,900 shares on 01/16/2026 at $10.8452. The trading plan was established to help the reporting person meet charitable commitments.
After these transactions, RK Fields Charitable 2022, LLC held 145,000 shares of common stock. As of 01/14/2026, Randall K. Fields also beneficially owned 3,483,955 common shares directly, plus additional common and Series B preferred stock indirectly through Riverview Financial Corp., his spouse, Fields Management, Inc., and other related holdings.
ReposiTrak director Robert W. Allen reported selling 8,280 shares of Series B Preferred Stock at $10.70 per share on 12/31/2025. After this transaction, he directly held 22,411 shares of Series B Preferred Stock. He also reported direct ownership of 199,147 shares of common stock, plus indirect holdings of 587,476 common shares through a trust and 2,775 common shares held by his spouse.
ReposiTrak, Inc. insider activity shows several transactions by entities associated with Chief Executive Officer Randall K. Fields, who is also a director and 10% owner. RK Fields Charitable 2022, LLC sold 5,000 shares of common stock on January 5, 2026 at a weighted average price of
ReposiTrak, Inc. insider Randall K. Fields, who serves as Chief Executive Officer, director, and a 10% owner, reported an automatic sale of company stock. On 12/31/2025, an affiliated entity, RK Fields Charitable 2022, LLC, sold 7,500 shares of common stock at a weighted average price of $12.3449 per share under a pre-established Rule 10b5-1 trading plan. The filing states that this trading plan was set up to help Mr. Fields meet certain charitable commitments. After the reported transaction, Mr. Fields continues to report substantial holdings in ReposiTrak common and preferred stock through multiple entities and family holdings.
ReposiTrak, Inc. director reports stock grant and sales
A director of ReposiTrak, Inc. (TRAK) reported several transactions in the company’s common stock. On November 5, 2025, he acquired 1,265 shares, issued in lieu of cash compensation for his board service for the quarter ended September 30, 2025. On December 22, 2025, he sold 1,641 shares at a weighted average price of $13.1981, and on December 23, 2025 he sold an additional 18,906 shares at a weighted average price of $13.164. After these transactions, he beneficially owned 561,869 shares of ReposiTrak common stock, held directly.
ReposiTrak, Inc. director Robert Allen reported receiving 1,265 shares of common stock on 11/05/2025. These shares were issued instead of cash payments for his service on the company’s Board of Directors for the quarter ended September 30, 2025.
After this transaction, he beneficially owned 199,147 shares of common stock directly, 587,476 shares indirectly through a trust, 2,775 shares indirectly through his spouse, and 39,704 shares of Series B preferred stock directly.
ReposiTrak, Inc. chief executive officer, director and 10% owner Randall K. Fields reported small insider stock sales executed under a Rule 10b5-1 trading plan. On 12/22/2025, an affiliated entity, RK Fields Charitable 2022, LLC, sold 3,000 shares of common stock at a weighted average price of $13.3687 per share. On 12/23/2025, the same entity sold an additional 4,500 shares at a weighted average price of $13.2618 per share. The filing explains that the trading plan was adopted by Fields, in his capacity as trustee of a charitable remainder unitrust, to help meet his charitable commitments. After these sales, Fields continues to beneficially own 3,483,955 shares of common stock directly, plus additional indirect holdings through family and affiliated entities.
TraK (TRAK) insider plans to sell common stock under Rule 144. A notice was filed for the proposed sale of 18,906 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $248,878.58, on or about 12/23/2025 on the NYSE. The issuer has 18,288,455 shares of this class outstanding. The shares to be sold were acquired between 2013 and 2015, mostly as restricted stock vesting under a registered plan in exchange for services, plus an open market purchase for cash. Over the past three months, the same seller disposed of 1,641 common shares for gross proceeds of $21,658.08. The seller represents that he is not aware of undisclosed material adverse information about the issuer.
A shareholder of TRAK has filed a notice of proposed sale of common stock under Rule 144. The filing covers 1,641 common shares, with an aggregate market value of $21,658.08, to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/22/2025. The shares are part of a total of 18,288,455 shares of this class outstanding. The seller originally acquired these shares on 09/19/2013 in an open market purchase from the issuer, paid in cash.
ReposiTrak, Inc. disclosed that its board has declared a quarterly cash dividend of $0.02 per share, which equates to $0.08 per share on an annual basis, on its common stock. The dividend is scheduled to be paid on or about February 13, 2026 to stockholders who are on record as of December 31, 2025. The company furnished this information through a press release attached as an exhibit, emphasizing that it is being provided for informational purposes and is not treated as filed for liability purposes under securities laws.
FAQ
What is the current stock price of ReposiTrak (TRAK)?
What is the market cap of ReposiTrak (TRAK)?
